{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:51:11Z","timestamp":1794358271140,"version":"4.9.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reappearance of ADAMTS13 deficiency. Some patients remain in remission despite recurring or persisting severe ADAMTS13 deficiency. In a prospective 2-year observational study, we investigated VWF MM patterns and ADAMTS13 in patients with iTTP in remission and at acute episodes. Of the 83 patients with iTTP, 16 suffered 22 acute episodes whereas 67 remained in clinical remission during follow-up, including 13 with ADAMTS13\u00a0&amp;lt;10% and 54 with ADAMTS13\u00a0\u226510%. High\u00a0-molecular weight to low-molecular weight VWF MM ratio based on sodium dodecyl sulfate-agarose gel electrophoresis was compared with ADAMTS13 activity. VWF MM ratio was significantly higher in patients in remission with &amp;lt;10% compared with \u226510% ADAMTS13 activity. Fourteen samples obtained from 13 to 50\u00a0days (interquartile range; median, 39) before acute iTTP onset (ADAMTS13\u00a0&amp;lt;10% in 9 patients and 10%-26% in 5) showed VWF MM ratios significantly higher than those from 13 patients remaining in remission with ADAMTS13\u00a0&amp;lt;10%. At acute iTTP onset, VWF MM ratio decreased significantly and was low in all patients despite &amp;lt;10% ADAMTS13. The VWF MM ratio does not depend exclusively on ADAMTS13 activity. The disappearance of high molecular weight VWF MMs resulting in low VWF MM ratio at iTTP onset may be explained by consumption of larger VWF MMs in the microcirculation. The very high VWF MM ratio preceding acute iTTP recurrence suggests that VWF processing is hampered more than in patients remaining in remission.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010028","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T19:24:30Z","timestamp":1688412270000},"page":"5091-5102","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"7","author":[{"given":"Tanja","family":"Falter","sequence":"first","affiliation":[{"name":"1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7532-8540","authenticated-orcid":false,"given":"Heidi","family":"Rossmann","sequence":"additional","affiliation":[{"name":"1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-9229","authenticated-orcid":false,"given":"Laure","family":"de Waele","sequence":"additional","affiliation":[{"name":"2Laboratory for Thrombosis Research, Interdisciplinary Research Facility, KU Leuven Campus Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Dekimpe","sequence":"additional","affiliation":[{"name":"2Laboratory for Thrombosis Research, Interdisciplinary Research Facility, KU Leuven Campus Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"von Auer","sequence":"additional","affiliation":[{"name":"3Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"},{"name":"4Department of Hematology, Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"M\u00fcller-Calleja","sequence":"additional","affiliation":[{"name":"1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"H\u00e4user","sequence":"additional","affiliation":[{"name":"1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Degreif","sequence":"additional","affiliation":[{"name":"1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Marandiuc","sequence":"additional","affiliation":[{"name":"5Transfusion Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Messmer","sequence":"additional","affiliation":[{"name":"3Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sprinzl","sequence":"additional","affiliation":[{"name":"6Medical Department I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-7931","authenticated-orcid":false,"given":"Karl J.","family":"Lackner","sequence":"additional","affiliation":[{"name":"1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-4035","authenticated-orcid":false,"given":"Kerstin","family":"Jurk","sequence":"additional","affiliation":[{"name":"3Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-8277","authenticated-orcid":false,"given":"Karen","family":"Vanhoorelbeke","sequence":"additional","affiliation":[{"name":"2Laboratory for Thrombosis Research, Interdisciplinary Research Facility, KU Leuven Campus Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-5154","authenticated-orcid":false,"given":"Bernhard","family":"L\u00e4mmle","sequence":"additional","affiliation":[{"name":"3Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany"},{"name":"7University Clinic of Hematology & Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"issue":"22","key":"2023091115441512000_bib1","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2023091115441512000_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023091115441512000_bib3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2023091115441512000_bib4","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation","volume":"78","author":"Moake","year":"1986","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"2023091115441512000_bib5","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"key":"2023091115441512000_bib6","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"2023091115441512000_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00108-010-2599-0","article-title":"[Thrombotic-thrombocytopenic purpura]","volume":"51","author":"Hellmann","year":"2010","journal-title":"Internist (Berl)"},{"issue":"5","key":"2023091115441512000_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.18127","article-title":"Mind and matter: the neurological complications of thrombotic thrombocytopenic purpura","volume":"197","author":"Shaw","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"2023091115441512000_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023091115441512000_bib10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023091115441512000_bib11","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"2023091115441512000_bib12","doi-asserted-by":"crossref","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"2023091115441512000_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"10","key":"2023091115441512000_bib14","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023091115441512000_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023091115441512000_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"Knoebl","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"13","key":"2023091115441512000_bib17","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2023091115441512000_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2023091115441512000_bib19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2023091115441512000_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2023091115441512000_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2012-02-412197","article-title":"Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies","volume":"120","author":"Fuchs","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2023091115441512000_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3324\/haematol.2016.149021","article-title":"Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura","volume":"101","author":"Cao","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2023091115441512000_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023091115441512000_bib24","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023091115441512000_bib25","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2007-08-108571","article-title":"The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2023091115441512000_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/asheducation-2004.1.407","article-title":"Recent advances in thrombotic thrombocytopenic purpura","volume":"2004","author":"Sadler","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023091115441512000_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2021.02.012","article-title":"Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19","volume":"201","author":"Turecek","year":"2021","journal-title":"Thromb Res"},{"key":"2023091115441512000_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/978-1-4939-7196-1_40","article-title":"Post-analytical issues in hemostasis and thrombosis testing","volume":"1646","author":"Favaloro","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"23","key":"2023091115441512000_bib29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023091115441512000_bib30","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2023091115441512000_bib31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1309\/75CQ-V7UX-4QX8-WXE7","article-title":"Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry","volume":"116","author":"Studt","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2023091115441512000_bib32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ijlh.13107","article-title":"Semi-automated von Willebrand factor multimer assay for von Willebrand disease: further validation, benefits and limitations","volume":"41","author":"Oliver","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2023091115441512000_bib33","first-page":"167","article-title":"Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use","volume":"40","author":"Pikta","year":"2021","journal-title":"J\u00a0Med Biochem"},{"issue":"6","key":"2023091115441512000_bib34","doi-asserted-by":"crossref","first-page":"e22416","DOI":"10.1002\/jcla.22416","article-title":"Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers","volume":"32","author":"Pikta","year":"2018","journal-title":"J\u00a0Clin Lab Anal"},{"issue":"1","key":"2023091115441512000_bib35","first-page":"115","article-title":"Establishing reference intervals for von Willebrand factor multimers","volume":"41","author":"Pikta","year":"2022","journal-title":"J\u00a0Med Biochem"},{"issue":"11","key":"2023091115441512000_bib36","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/diagnostics11112153","article-title":"Multimer analysis of von Willebrand factor in von Willebrand disease with a hydrasys semi-automatic analyzer-single-center experience","volume":"11","author":"Skornova","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"2023091115441512000_bib37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/rth2.12141","article-title":"Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers","volume":"2","author":"Bowyer","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2023091115441512000_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"14","key":"2023091115441512000_bib39","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an International Working Group Consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023091115441512000_bib40","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bodo","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023091115441512000_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"2023091115441512000_bib42","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1538-7836.2006.01904.x","article-title":"Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods","volume":"4","author":"Kremer Hovinga","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023091115441512000_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2011.051433","article-title":"Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura","volume":"97","author":"Froehlich-Zahnd","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"2023091115441512000_bib44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jth.14747","article-title":"Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen","volume":"18","author":"Dekimpe","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2023091115441512000_bib45","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood-2010-04-280479","article-title":"Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)","volume":"116","author":"Feys","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2023091115441512000_bib46","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/jth.13149","article-title":"Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13","volume":"13","author":"Deforche","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023091115441512000_bib47","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/bloodadvances.2019001375","article-title":"Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function","volume":"4","author":"Schelpe","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2023091115441512000_bib48","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1055\/s-0038-1668545","article-title":"Relapse rate in survivors of acute autoimmune thrombotic thrombocytopenic purpura treated with or without rituximab","volume":"118","author":"Falter","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"2023091115441512000_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.2019000954","article-title":"How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns","volume":"134","author":"Mazepa","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2023091115441512000_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2023091115441512000_bib51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"Kuhne","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"13","key":"2023091115441512000_bib52","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2023091115441512000_bib53","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/jth.15892","article-title":"Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study","volume":"20","author":"Scully","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"20","key":"2023091115441512000_bib54","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2023091115441512000_bib55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023091115441512000_bib56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"2023091115441512000_bib57","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2019.237396","article-title":"Histone-induced thrombotic thrombocytopenic purpura in adamts13 (-\/-) zebrafish depends on von Willebrand factor","volume":"105","author":"Zheng","year":"2020","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5091\/2077097\/blooda_adv-2023-010028-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5091\/2077097\/blooda_adv-2023-010028-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:44:53Z","timestamp":1694447093000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/5091\/496692\/A-novel-von-Willebrand-factor-multimer-ratio-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":57,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010028","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}